Lofexidine
Lucemyra (lofexidine) is a small molecule pharmaceutical. Lofexidine was first approved as Lucemyra on 2018-05-16. It is used to treat substance withdrawal syndrome in the USA. It is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Lucemyra
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lofexidine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUCEMYRA | US WorldMeds | N-209229 RX | 2018-05-16 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lucemyra | New Drug Application | 2022-03-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| substance withdrawal syndrome | EFO_0005800 | D013375 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LOFEXIDINE HYDROCHLORIDE, LUCEMYRA, USWM | |||
| 2023-05-16 | NCE | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
203 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 3 | 5 | 21 | 33 | 17 | 75 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 3 | 3 | 3 | 7 | 4 | 18 |
| Depression | D003863 | F33.9 | 1 | 2 | 3 | 9 | 2 | 16 | |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 1 | 3 | 2 | 6 |
| Treatment-resistant depressive disorder | D061218 | — | 1 | 1 | 3 | 1 | 6 | ||
| Mania | D000087122 | F30 | — | — | 3 | 2 | 1 | 6 | |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | 2 | 1 | 4 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | 1 | — | 3 |
| Psychotic disorders | D011618 | F20.81 | — | 1 | — | 2 | — | 3 | |
| Dementia | D003704 | F03 | — | — | 1 | 1 | — | 2 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 3 | 1 | — | — | 3 |
| Attempted suicide | D013406 | EFO_0004321 | T14.91 | — | 2 | 2 | — | — | 2 |
| Suicide | D013405 | — | 1 | 1 | — | 1 | 2 | ||
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Autism spectrum disorder | D000067877 | F84.0 | — | — | 1 | — | — | 1 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | 1 | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | — | 1 |
| Machado-joseph disease | D017827 | EFO_0004135 | — | 1 | 1 | — | — | 1 | |
| Conduct disorder | D019955 | EFO_0004216 | F91 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | 4 | 5 | — | — | — | 6 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 3 | — | — | — | 3 |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | 1 | 2 | |
| Small cell lung carcinoma | D055752 | 1 | 1 | — | — | 1 | 2 | ||
| Spinocerebellar ataxias | D020754 | 1 | 1 | — | — | — | 2 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | 1 | 1 | — | — | — | 1 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | 1 | |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | 1 | — | — | — | 1 |
| Dysthymic disorder | D019263 | EFO_0008623 | F34.1 | — | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | 1 | 2 | |
| Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Esophageal neoplasms | D004938 | C15 | 1 | — | — | — | — | 1 | |
| Megakaryoblastic leukemia acute | D007947 | C94.2 | 1 | — | — | — | — | 1 | |
| Monocytic leukemia acute | D007948 | 1 | — | — | — | — | 1 | ||
| Myelomonocytic leukemia acute | D015479 | C92.5 | 1 | — | — | — | — | 1 | |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 1 | — | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
| Type c niemann-pick disease | D052556 | Orphanet_646 | E75.242 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nonvital tooth | D019553 | — | — | — | — | 3 | 3 | ||
| Prosthesis failure | D011475 | — | — | — | — | 2 | 2 | ||
| Tooth wear | D057085 | — | — | — | — | 2 | 2 | ||
| Healthy volunteers/patients | — | — | — | — | — | 1 | 1 | ||
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | — | 1 | 1 |
| Vitiligo | D014820 | EFO_0004208 | L80 | — | — | — | — | 1 | 1 |
| Tooth discoloration | D014075 | K03.6 | — | — | — | — | 1 | 1 | |
| Tooth loss | D016388 | — | — | — | — | 1 | 1 | ||
| Dental implants | D015921 | — | — | — | — | 1 | 1 | ||
| Sleep bruxism | D020186 | G47.63 | — | — | — | — | 1 | 1 |
Show 31 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LOFEXIDINE |
| INN | lofexidine |
| Description | Lofexidine is a member of imidazoles, a dichlorobenzene, an aromatic ether and a carboxamidine. It has a role as an alpha-adrenergic agonist and an antihypertensive agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(Oc1c(Cl)cccc1Cl)C1=NCCN1 |
Identifiers
| PDB | — |
| CAS-ID | 31036-80-3 |
| RxCUI | 28863 |
| ChEMBL ID | CHEMBL17860 |
| ChEBI ID | 51368 |
| PubChem CID | 30668 |
| DrugBank | DB04948 |
| UNII ID | UI82K0T627 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADRA2B
ADRA2B
ADRA2A
ADRA2A
ADRA2C
ADRA2C
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 608 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,902 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more